- In February 2025, Axion BioSystems, a leading provider of microelectrode array technology, announced the launch of its Maestro Edge+ platform, an upgraded version of its in vitro electrophysiology system. The new system features enhanced signal resolution, improved compatibility with high-throughput assays, and AI-powered data analysis tools for more precise neurophysiological research
- In December 2024, MultiChannel Systems (MCS) introduced its next-generation MEA2100-HTS System, designed for high-throughput screening applications in drug discovery. The system integrates advanced electrode technology, allowing simultaneous recordings from thoU.S.nds of neurons with enhanced sensitivity and noise reduction
- In November 2024, NeuroNexus Technologies unveiled its FlexMEA-X Series, a new line of flexible microelectrode arrays optimized for in vitro studies of neurodegenerative diseases. The innovative design enhances electrode durability and signal fidelity, making it ideal for long-term neuronal culture experiments
- In October 2024, MaxWell Biosystems launched its MaxTwo+, a high-resolution microelectrode array system designed for large-scale neural network recordings. This system supports real-time neural activity monitoring with improved data processing capabilities, catering to pharmaceutical research and brain-computer interface studies
- In September 2024, Harvard University’s Wyss Institute announced a breakthrough in 3D organ-on-chip technology, integrating microelectrode arrays with brain organoid models. This development allows researchers to study complex neuronal interactions in vitro with unprecedented accuracy, accelerating drug discovery for neurodegenerative and psychiatric disorders
